, 2011; fuster, - weill cornell brain and spine
TRANSCRIPT
•
Rogers, Circulation, 2011; Fuster, Circulation, 2006
•
–
–
–
–
•
Fuster, Circulation, 2006
•
•
–
–
Fuster, Circulation, 2006
•
Fuster, Circulation, 2006
•
–
–
–
•
•
Lip, Chest, 2010
•
–
–
–
–
–
–
–
Friberg, Circulation, 2012
0
2
4
6
8
10
12
14
1 2 3 4 5 6 7 8 9 10
An
nu
al R
isk
of
Stro
ke
CHA2DS2VASc Score
Lip, Chest, 2010
Pisters, Chest, 2010
•
–
–
–
–
–
–
–
Pisters, Chest, 2010
0
2
4
6
8
10
12
14
1 2 3 4 5 6
An
nu
al R
isk
of
Ble
ed
ing
HASBLED Score
Figure.
The net clinical benefit of warfarin by age group (top) and CHADS2 score (bottom). Net clinical
benefit is plotted as the adjusted, weighted adverse events prevented per 100 person-years by
warfarin treatment, according to age group and CHADS 2 score, respectively. Intracranial
hemorrhage is weighted as 1.5 times the value of thromboembolism (see Methods section).
Stratified rates for CHADS2 score are not further adjusted. CHADS2 = Congestive Heart
Failure/Hypertension/Age/Diabetes/Prior Stroke2.
Singer et al. Page 12
Ann Intern Med. Author manuscript; available in PMC 2010 March 1.
NIH
-PA
Au
tho
r Ma
nuscrip
tN
IH-P
A A
uth
or M
anu
scrip
tN
IH-P
A A
uth
or M
an
uscrip
t
Fang, Ann Intern Med, 2009
•
•
•
•
–
–
–
•
–
•
–
Dabigatran Rivaroxaban Apixaban
Average age 72 73 70
Average CHADS2 2.1 3.5 2.1
Prior stroke/TIA 20% 55% 20%
Connolly, NEJM, 2009; Granger, NEJM, 2011; Patel, NEJM, 2011
Connolly, NEJM, 2009; Granger, NEJM, 2011; Patel, NEJM, 2011
Dabigatran Rivaroxaban Apixaban
Blinding Single Double Double
Sample size 18,113 14,264 18,201
Follow-up 2.0 yrs 1.9 yrs 1.8 yrs
Mean TTR 64% 55% 62%
Discontinued 21 v. 17% 24 v. 22% 25 v. 28%
Connolly, NEJM, 2009; Granger, NEJM, 2011; Patel, NEJM, 2011
Dabigatran Rivaroxaban Apixaban
Stroke: 0.66 0.79 0.79
ICH: 0.40 0.67 0.42
MI: 1.38 0.81 0.88
Death: 0.88 0.92 0.89
Connolly, NEJM, 2009; Granger, NEJM, 2011; Patel, NEJM, 2011
Dabigatran Rivaroxaban Apixaban
Stroke:
Active 1.11% 1.7% 1.27%
Warfarin 1.69% 2.2% 1.60%
ICH:
Active 0.30% 0.5% 0.33%
Warfarin 0.74% 0.7% 0.80%
Hart, Stroke, 2012; FDA, fda.gov, 2012
•
•
Freeman, Ann Intern Med, 2011; Shah, Circulation, 2011; Kamel, Stroke, 2011; Lee, Am J Cardiol, 2012; Lee, PLoS One, 2012; Kamel, Neurology, 2012
•
–
–
–
•
•
You, Chest, 2012; Cairns, Can J Cardiol, 2012
•
•
•
Donze, Am J Med, 2012; Healey, NEJM, 2012; You, Chest, 2012;
•
•
•
•
•
•
•
•